NLRP3 and myocardial infarction: Colchicine: It has been demonstrated that this well-known anti-inflammatory medication, which is used to treat gout and pericarditis, inhibits the NLRP3 inflammasome on several levels. Its effectiveness in lowering cardiovascular events in patients with post-MI and chronic coronary syndrome, respectively, was proven by the seminal COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low-Dose Colchicine 2 Trial) trials [33,34].